Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03798626 · ClinicalTrials.gov registry record · Phase 1
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 167
- Enrollment target
NCT03798626: Completed Phase 1 study, sponsored by Novartis Pharmaceuticals.
NCT03798626 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 167 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (178% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03798626, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 167 participants
- Enrollment target
Study Summary
This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma, and the preliminary efficacy of gevokizumab in combination with the SOC anti-cancer therapy in subjects with mCRC and mGEC.
Primary Outcome
Log scale change of hs-CRP at Day 15 from baseline
Interventions
- DRUG Bevacizumab
- DRUG Ramucirumab
- DRUG FOLFIRI
- DRUG Modified FOLFOX6
- DRUG Gevokizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 167 participants |
| Start Date | 2019-05-22 |
| Est. Completion | 2025-02-05 |
| Phase | Phase 1 |
What the finished NCT03798626 record still lists
NCT03798626 is an interventional study that assigns participants to a tested intervention. The registered 167 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (178% higher).
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT03798626 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03798626 about?
NCT03798626 is a clinical study titled "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers". This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma, and t...
What is the current status of trial NCT03798626?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 167 participants. The study started on 2019-05-22. Estimated completion is 2025-02-05.
What interventions are being tested in trial NCT03798626?
The interventions under investigation include: Bevacizumab (DRUG), Ramucirumab (DRUG), FOLFIRI (DRUG), Modified FOLFOX6 (DRUG), Gevokizumab (DRUG).
Who is sponsoring clinical trial NCT03798626?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03798626's enrollment target sits among peer trials
167 330th of 2000 higher than 1,671 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04248283 · 167 participants · NA
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
- NCT04552509 · 167 participants · NA
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
- NCT05516277 · 167 participants · NA
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
- NCT02118922 · 168 participants
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI